UA115678C2 - МУТАНТНИЙ ПОЛІПЕПТИД TGFβ ТА ФАРМАЦЕВТИЧНА КОМПОЗИЦІЯ, ЩО ЙОГО МІСТИТЬ - Google Patents

МУТАНТНИЙ ПОЛІПЕПТИД TGFβ ТА ФАРМАЦЕВТИЧНА КОМПОЗИЦІЯ, ЩО ЙОГО МІСТИТЬ

Info

Publication number
UA115678C2
UA115678C2 UAA201505566A UAA201505566A UA115678C2 UA 115678 C2 UA115678 C2 UA 115678C2 UA A201505566 A UAA201505566 A UA A201505566A UA A201505566 A UAA201505566 A UA A201505566A UA 115678 C2 UA115678 C2 UA 115678C2
Authority
UA
Ukraine
Prior art keywords
tgfβ
amino acid
relates
polypeptides derived
fibrosis
Prior art date
Application number
UAA201505566A
Other languages
English (en)
Inventor
Монсон Калєт Лєон
Портілла Таня Карменате
Меріньо Амаурі Пупо
Родрігес Саумель Перес
Original Assignee
Сентро Де Інмунологіа Молекулар
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=49765213&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=UA115678(C2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Сентро Де Інмунологіа Молекулар filed Critical Сентро Де Інмунологіа Молекулар
Publication of UA115678C2 publication Critical patent/UA115678C2/uk

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1841—Transforming growth factor [TGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/495—Transforming growth factor [TGF]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Biomedical Technology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)

Abstract

Винахід стосується мутантного поліпептиду TGF(, який здійснює антагоністичний вплив на активність природних лігандів TGFβ, опосередковану рецептором ALK5, який включає мутацію за типом амінокислотної заміни в положеннях амінокислотних залишків W30, LI01, 151 і L51 нативних лігандів TGFβ1, TGFβ2 або TGFβ3 людини. Даний винахід також стосується фармацевтичної композиції, яка призначена для лікування раку, захворювань, які супроводжуються фіброзом, і хронічних інфекційних захворювань.
UAA201505566A 2012-11-09 2013-10-30 МУТАНТНИЙ ПОЛІПЕПТИД TGFβ ТА ФАРМАЦЕВТИЧНА КОМПОЗИЦІЯ, ЩО ЙОГО МІСТИТЬ UA115678C2 (uk)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CU20120158A CU24181B1 (es) 2012-11-09 2012-11-09 POLIPÉPTIDOS DERIVADOS DEL TGFß
PCT/CU2013/000007 WO2014071894A1 (es) 2012-11-09 2013-10-30 POLIPÉPTIDOS DERIVADOS DEL TGFβ Y SUS USOS

Publications (1)

Publication Number Publication Date
UA115678C2 true UA115678C2 (uk) 2017-12-11

Family

ID=49765213

Family Applications (1)

Application Number Title Priority Date Filing Date
UAA201505566A UA115678C2 (uk) 2012-11-09 2013-10-30 МУТАНТНИЙ ПОЛІПЕПТИД TGFβ ТА ФАРМАЦЕВТИЧНА КОМПОЗИЦІЯ, ЩО ЙОГО МІСТИТЬ

Country Status (28)

Country Link
US (1) US9701730B2 (uk)
EP (1) EP2918284B1 (uk)
JP (2) JP6298823B2 (uk)
KR (1) KR102093494B1 (uk)
CN (1) CN104902916B (uk)
AR (1) AR093391A1 (uk)
AU (1) AU2013344022B2 (uk)
BR (1) BR112015010145B1 (uk)
CA (1) CA2887455C (uk)
CL (1) CL2015001252A1 (uk)
CO (1) CO7400865A2 (uk)
CU (1) CU24181B1 (uk)
EA (1) EA031990B1 (uk)
ES (1) ES2857176T3 (uk)
HK (1) HK1213781A1 (uk)
IL (1) IL238621B (uk)
JO (1) JO3502B1 (uk)
MX (1) MX366060B (uk)
MY (1) MY173078A (uk)
NZ (1) NZ707850A (uk)
PE (1) PE20150890A1 (uk)
PH (1) PH12015500807A1 (uk)
SG (1) SG11201502980VA (uk)
TN (1) TN2015000129A1 (uk)
TW (1) TWI615404B (uk)
UA (1) UA115678C2 (uk)
WO (1) WO2014071894A1 (uk)
ZA (1) ZA201504462B (uk)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3541409A4 (en) * 2016-11-18 2020-06-17 University of Pittsburgh - of The Commonwealth System of Higher Education MANIPULATED TGF-BETA MONOMERS AND THEIR USE FOR INHIBITING TGF-BETA SIGNALING
PL238850B1 (pl) * 2017-10-19 2021-10-11 Calther Polska Spolka Z Ograniczona Odpowiedzialnoscia Aktywna forma transformującego czynnika wzrostu beta 1 (TGFβ1) do zastosowania w leczeniu pacjentów z glejakami wielopostaciowymi, w przypadku których to glejaków ponad 5% komórek nowotworowych jest EGFRvIII-pozytywna

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999065948A1 (en) * 1998-06-16 1999-12-23 Biogen, Inc. Variant type ii tgf-beta receptor fusion proteins and methods
CA2344277A1 (en) 1998-09-22 2000-03-30 University Of Maryland, Baltimore Cystine knot growth factor mutants
US6677432B1 (en) * 1998-10-07 2004-01-13 Stryker Corporation Mutations of the C-terminal portion of TGF-β superfamily proteins
ES2146552B1 (es) * 1998-11-24 2001-04-16 Inst Cientifico Tecnol Navarra Peptidos inhibidores de tgf/31
JP2008509888A (ja) * 2004-06-30 2008-04-03 モレキュラー ロジックス，インコーポレイテッド 上皮成長因子受容体アンタゴニストおよび使用方法
US7795389B2 (en) * 2004-09-28 2010-09-14 The Board Of Regents Of The University Of Texas System Antagonizing TGF-beta activity with various ectodomains TGF-beta receptors used in combination or as fusion proteins
CN101365712A (zh) * 2005-01-11 2009-02-11 莫勒丘尔洛吉克斯有限公司 Pan-HER拮抗剂及其使用方法
GB0724051D0 (en) * 2007-12-08 2008-01-16 Medical Res Council Mutant proteins and methods for producing them
CN102958531A (zh) * 2010-04-22 2013-03-06 耶路撒冷希伯来大学伊森姆研究发展公司 高亲和力瘦蛋白和瘦蛋白拮抗剂

Also Published As

Publication number Publication date
CN104902916B (zh) 2018-04-13
PE20150890A1 (es) 2015-06-10
KR20150083848A (ko) 2015-07-20
BR112015010145B1 (pt) 2022-06-07
MX366060B (es) 2019-06-26
EP2918284B1 (en) 2021-02-17
EA031990B1 (ru) 2019-03-29
AU2013344022B2 (en) 2016-12-15
WO2014071894A1 (es) 2014-05-15
BR112015010145A2 (uk) 2017-08-22
MX2015005875A (es) 2015-09-10
IL238621A0 (en) 2015-06-30
JO3502B1 (ar) 2020-07-05
KR102093494B1 (ko) 2020-03-26
TWI615404B (zh) 2018-02-21
US9701730B2 (en) 2017-07-11
HK1213781A1 (zh) 2016-07-15
ES2857176T3 (es) 2021-09-28
JP2018111703A (ja) 2018-07-19
CO7400865A2 (es) 2015-09-30
CA2887455A1 (en) 2014-05-15
JP6298823B2 (ja) 2018-03-20
AU2013344022A1 (en) 2015-05-28
JP6608473B2 (ja) 2019-11-20
CU20120158A7 (es) 2014-06-27
EA201590914A1 (ru) 2015-09-30
MY173078A (en) 2019-12-25
CN104902916A (zh) 2015-09-09
TN2015000129A1 (en) 2016-10-03
US20150284441A1 (en) 2015-10-08
ZA201504462B (en) 2018-11-28
CL2015001252A1 (es) 2015-07-17
AR093391A1 (es) 2015-06-03
NZ707850A (en) 2019-08-30
PH12015500807A1 (en) 2015-06-08
EP2918284A1 (en) 2015-09-16
TW201431875A (zh) 2014-08-16
CA2887455C (en) 2022-05-17
JP2015535000A (ja) 2015-12-07
IL238621B (en) 2019-12-31
CU24181B1 (es) 2016-04-25
SG11201502980VA (en) 2015-06-29

Similar Documents

Publication Publication Date Title
PH12020550205A1 (en) IL-22 POLYPEPTIDES AND IL-22 Fc FUSION PROTEINS AND METHODS OF USE
MX2014015257A (es) Proteinas del factor 21 de crecimiento de fibroblasto.
MY187486A (en) Cysteine protease
MX2016003942A (es) Proteinas de union a desmogelina 2 (dsg2) y usos de los mismos.
MX2017003211A (es) Anticuerpos anti-met y composiciones.
EA201990558A3 (ru) Доставка нацеленных на экзон 2 полинуклеотидных конструкций u7snrna при помощи рекомбинантного аденоассоциированного вируса
JP2015514395A5 (uk)
EP3363458A3 (en) A peptide
MX2013008702A (es) Composiciones que contienen anticuerpos glicosilados y sus usos.
PH12020551019A1 (en) IL-22 Fc FUSION PROTEINS AND METHODS OF USE
MX2018014023A (es) Compuestos de citocina inhibidora de macrofagos 1 (mic-1) y uso de estos.
MX2020011333A (es) Uso terapeutico de proteinas morfogeneticas oseas.
WO2017006052A3 (fr) UTILISATION DE FRAGMENTS Fc MODIFIÉS EN IMMUNOTHÉRAPIE
EA201401278A1 (ru) Композиции из олигонуклеотидных хелатных комплексов и полипептидов и способы
MX2019013801A (es) Compuestos de citocina inhibidora de macrofagos-1 (mic-1) y usos de estos.
WO2020123795A3 (en) Anellosomes for delivering protein replacement therapeutic modalities
PH12017500742A1 (en) Statherin peptides
UA115678C2 (uk) МУТАНТНИЙ ПОЛІПЕПТИД TGFβ ТА ФАРМАЦЕВТИЧНА КОМПОЗИЦІЯ, ЩО ЙОГО МІСТИТЬ
MX2018000023A (es) Particulas semejantes a virus recombinantes que utilizan la proteina gag del virus de inmunodeficiencia bovina.
PH12015502100A1 (en) Reducing the risk of autoimmune disease
GB201118201D0 (en) Novel peptides
MX2020008295A (es) Polipeptidos, composiciones y sus usos.
WO2015054217A3 (en) Methods and uses for reducing an allergic response in a subject
PH12016500509A1 (en) Compositions comprising heterogeneous populations of recombinant human clotting factor xa proteins
EA202090582A3 (ru) Полипептиды il-22, химерные белки il-22 fc и их применение